Naiyer Rizvi, MD
Memorial Sloan Kettering Cancer Center
9
6
8
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+5 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Aminah Jatoi, MD
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Jimmy Hwang, MD
Georgetown University
Shared therapeutic areas:
Worked with same sponsors:
Chao Huang, MD
University of Kansas
Shared therapeutic areas:
Worked with same sponsors:
David B. Solit, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Jaroslaw Jac, M.D.
AVEO Pharmaceuticals, Inc.
Shared therapeutic areas:
Worked with same sponsors:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
You Lu, MD
West China Hospital
Shared therapeutic areas:
Yongchang Zhang, MD
Hunan Cancer Hospital
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer
Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy
Gefitinib and Docetaxel in Treating Patients With Advanced Solid Tumors
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
All 9 trials loaded